US 11,919,967 B2
Anti-presenilin antibody for use in the prevention and/or treatment of cancer
Rogelio Gonzalez Sarmiento, Salamanca (ES); Miguel Rodriguez Manotas, Torres de Cotillas (ES); Javier Fernandez Mateos, Salamanca (ES); Juan Carlos Gallar Ruiz, Torres de Cotillas (ES); and David Florenciano Gomez, Torres de Cotillas (ES)
Assigned to ALZHEIMUR 2012 S.L., Murcia (ES); FUNDACION UNIVERSITARIA SAN ANTONIO, Guadalupe (ES); IBSAL (INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANC, Salamanca (ES); and UNIVERSIDAD DE SALAMANCA, Salamanca (ES)
Appl. No. 16/636,416
Filed by ALZHEIMUR 2012 S.L., Murcia (ES); FUNDACIÓN UNIVERSITARIA SAN ANTONIO, Murcia (ES); IBSAL (INSTITUTO DE INVESTIGACIÓN BIOMEDICA DE SALAMANCA), Salamanca (ES); and UNIVERSIDAD DE SALAMANCA, Salamanca (ES)
PCT Filed Aug. 3, 2018, PCT No. PCT/ES2018/070544
§ 371(c)(1), (2) Date Feb. 4, 2020,
PCT Pub. No. WO2019/025659, PCT Pub. Date Feb. 7, 2019.
Claims priority of application No. 17382546 (EP), filed on Aug. 4, 2017.
Prior Publication US 2020/0354470 A1, Nov. 12, 2020
Int. Cl. C07K 16/30 (2006.01); C07K 16/38 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/30 (2013.01) [C07K 16/38 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/73 (2013.01)] 4 Claims
 
1. A pharmaceutical composition for treating cancer, comprising:
a polyclonal antibody or fragment thereof that specifically binds to SEQ ID NO: 1; Apo2L (Trail); and
a pharmaceutically acceptable carrier and/or excipient.